TY - JOUR
T1 - Lymphadenectomy for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma
AU - Sathianathen, Niranjan J.
AU - Risk, Michael C.
AU - Konety, Badrinath R.
PY - 2018/5
Y1 - 2018/5
N2 - There are currently no reported randomized trials that characterize the staging or therapeutic benefit of performing a lymph node dissection in either bladder cancer or upper tract urothelial carcinoma. Several unanswered questions remain in this domain focused on the indications and patient selection for pelvic lymph node dissection, extent of dissection, its impact on outcome, and potential risks. However, the results of observational studies suggest that the burden of metastasis is high in both diseases when muscle invasive and performing a lymphadenectomy can provide prognostic information and yield therapeutic benefit.
AB - There are currently no reported randomized trials that characterize the staging or therapeutic benefit of performing a lymph node dissection in either bladder cancer or upper tract urothelial carcinoma. Several unanswered questions remain in this domain focused on the indications and patient selection for pelvic lymph node dissection, extent of dissection, its impact on outcome, and potential risks. However, the results of observational studies suggest that the burden of metastasis is high in both diseases when muscle invasive and performing a lymphadenectomy can provide prognostic information and yield therapeutic benefit.
KW - Cystectomy
KW - Lymph node dissection
KW - Transitional cell carcinoma
KW - Urinary bladder neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85042188349&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042188349&partnerID=8YFLogxK
U2 - 10.1016/j.ucl.2017.12.006
DO - 10.1016/j.ucl.2017.12.006
M3 - Review article
C2 - 29650137
AN - SCOPUS:85042188349
SN - 0094-0143
VL - 45
SP - 215
EP - 228
JO - Urologic Clinics of North America
JF - Urologic Clinics of North America
IS - 2
ER -
